The stock of Celldex Therapeutics Inc. (CLDX) has seen a -16.13% decrease in the past week, with a -27.20% drop in the past month, and a -15.87% decrease in the past quarter. The volatility ratio for the week is 7.72%, and the volatility levels for the past 30 days are at 8.56% for CLDX. The simple moving average for the past 20 days is -24.62% for CLDX’s stock, with a -22.30% simple moving average for the past 200 days.
Is It Worth Investing in Celldex Therapeutics Inc. (NASDAQ: CLDX) Right Now?
The 36-month beta value for CLDX is at 1.57. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLDX is 64.21M, and currently, shorts hold a 13.10% of that float. The average trading volume for CLDX on October 03, 2024 was 947.88K shares.
CLDX) stock’s latest price update
Celldex Therapeutics Inc. (NASDAQ: CLDX)’s stock price has gone decline by -6.76 in comparison to its previous close of 32.40, however, the company has experienced a -16.13% decrease in its stock price over the last five trading days. zacks.com reported 2024-09-26 that Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Goldman repeating the rating for CLDX by listing it as a “Neutral.” The predicted price for CLDX in the upcoming period, according to Goldman is $45 based on the research report published on September 30, 2024 of the current year 2024.
Stifel gave a rating of “Buy” to CLDX, setting the target price at $58 in the report published on June 18th of the current year.
CLDX Trading at -20.76% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.19% of loss for the given period.
Volatility was left at 8.56%, however, over the last 30 days, the volatility rate increased by 7.72%, as shares sank -32.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.22% lower at present.
During the last 5 trading sessions, CLDX fell by -16.13%, which changed the moving average for the period of 200-days by -16.43% in comparison to the 20-day moving average, which settled at $39.36. In addition, Celldex Therapeutics Inc. saw -23.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Martin Samuel Bates, who sale 17,172 shares at the price of $35.42 back on Jun 14 ’24. After this action, Martin Samuel Bates now owns 28,125 shares of Celldex Therapeutics Inc., valued at $608,315 using the latest closing price.
Crowley Elizabeth, the SR. VP & CPDO of Celldex Therapeutics Inc., sale 30,000 shares at $34.87 during a trade that took place back on Jun 14 ’24, which means that Crowley Elizabeth is holding 9,074 shares at $1,045,962 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -19.67 for the present operating margin
- 0.63 for the gross margin
The net margin for Celldex Therapeutics Inc. stands at -18.09. The total capital return value is set at -0.2. Equity return is now at value -27.53, with -26.24 for asset returns.
Based on Celldex Therapeutics Inc. (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -50.94. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -52.51.
Currently, EBITDA for the company is -139.03 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 236.35. The receivables turnover for the company is 1.31for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.36.
Conclusion
In conclusion, Celldex Therapeutics Inc. (CLDX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
